

ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

Company	2019/11/20 22:01:18
	Price 184.96 USD
	Difference  -0.14%(-0.26)



Contact Details

ALLERGAN PLC
Daphne Karydas
Clonsaugh Business and
Technology Park
- Dublin, D17 E400, Ireland

Tel: +1-862-261-7000
Fax: -
Web: <http://www.allergan.com>
E-mail: -

Company Profile

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model -- Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2018		2017		2016	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	6,475,400,000		11,376,700,000		17,857,900,000	
Common stock capital		0		0		0
Fixed assets	-		-		-	
Equity capital of a company		65,131,000,000		73,837,100,000		76,200,500,000
Cash and cash equivalents	880,400,000		1,817,200,000		1,724,000,000	
Accrued liabilities		-		-		-
Other assets	2,852,800,000		349,500,000		309,100,000	
Current liabilities		5,727,900,000		9,848,100,000		7,874,700,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		-		-		-
Total assets	101,787,600,000	101,787,600,000	118,341,900,000	118,341,900,000	128,986,300,000	128,986,300,000

Balance notes

	2018	2017	2016
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	16,900	17,800	16,700
Equity ratio	64.00%	62.41%	59.08%
Debt-equity ratio	56.24%	60.24%	69.25%

Others

	2018	2017	2016
Tax Expense Rate	25.82%	64.22%	66.98%

ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

Income statement

	2018	2017	2016
Turnover	15,787,400,000	15,940,700,000	14,570,600,000
Net income	-5,096,400,000	-4,125,500,000	14,973,400,000
EBIT	-5,410,980,880	-8,452,597,200	-1,450,810,160
Operating income before taxes	-6,856,900,000	-10,386,400,000	-2,832,000,000
Cash Flow	5,640,100,000	5,873,400,000	1,425,300,000
Net interest income	-866,000,000	-1,027,900,000	-1,225,700,000
Research and development expenses	2,266,200,000	2,100,100,000	2,575,700,000
Income taxes	-1,770,700,000	-6,670,400,000	-1,897,000,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	843,738	808,856	788,034

Board of Directors

Brenton L. Saunders	Chairman of Supervisory Board
Thomas C. Freyman	Member of Supervisory Board
Robert J. Hugin	Member of Supervisory Board
Peter J. McDonnell	Member of Supervisory Board
Nesli Basgoz	Member of Supervisory Board
Michael E. Greenberg	Member of Supervisory Board
Joseph H. Boccuzzi	Member of Supervisory Board
Christopher W. Bodine	Member of Supervisory Board
Christopher J. Coughlin	Member of Supervisory Board
Carol Anthony (John) Davidson	Member of Supervisory Board
Adriane M. Brown	Member of Supervisory Board

Members of Management Board

Brenton L. Saunders	Chairman of Managing Board
Wayne R. Swanton	Member of Executive Committee
Matt Walsh	Member of Executive Committee
Kellie Sears	Member of Executive Committee
Bob Bailey	Member of Executive Committee
Bill Meury	Member of Executive Committee
Alex Kelly	Member of Executive Committee
C. David Nicholson	Member of Executive Committee